Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: 0.17 + web  Related to the article below (Last Update: 8/4/2008)

Triad Guaranty Inc. Reports Second Quarter Loss as Reported ...
MarketWatch -
For more information, please visit the Company's web site at www.triadguaranty.com. Diluted realized investment gains (losses) per share, net of taxes, ...TGIC
College of Art Buys Area Homes
Memphis Daily News,  USA - 55 minutes ago
Last month it spent $175000 for the 2040-square-foot home that sits on 0.17 acres at 148 N. Tucker St.; $187000 for the 2232-square-foot home that sits on ...
Lydall Announces Financial Results for the Second Quarter and Six ...
CNNMoney.com -
The call may be accessed in a listen-only mode at 877-440-5804 and will be webcast live on the Company's web site www.lydall.com under the Investor ...LDL
Equity One Reports Second Quarter 2008 Operating Results
WELT ONLINE, Germany - Jul 29, 2008
CONFERENCE CALL/WEB CAST INFORMATION We will host a conference call on Wednesday, July 30, 2008, at 9:00 am EST to review the 2008 second quarter earnings ...EQY - COL:EQIT
BlueLinx Announces Second-Quarter Results
MarketWatch - Jul 30, 2008
Investors can listen to the conference call and view the accompanying slide presentation by going to the BlueLinx web site, www. ...
thinkorswim Group Inc. Reports Second Quarter Financial Results CNNMoney.com (press release)
TSMC Reports Second Quarter EPS of NT$1.12 PR Newswire (press release)
Nexity Financial Second Quarter Results MarketWatch
all 254 news articles »  TSM - BXC - NXTY
Firefox 3 chipping away Safari market share, summer browsing ...
TG Daily - Aug 1, 2008
... most notably Apple's Safari (which showed a 0.17 point decline in July), Opera (0.04 point decline), and other web browsers, possible earlier Firefox ...
Actel Announces Second Quarter 2008 Financial Results
CNNMoney.com - Jul 29, 2008
A live web cast and replay of the call will be available. Web cast and replay access information as well as financial and other statistical information can ...ACTL
June 2008 Quarterly Activities and Cashflow Report
Sydney Morning Herald, Australia - Jul 21, 2008
The results were reported during the June quarter and included the following excellent intersections: BL08-15: 68.60m @ 1.29g/t Pt+Pd, 0.17% Cu & 0.17% Ni ...ASX:MMB
Euronet Worldwide Reports Second Quarter 2008 Financial Results
FOXBusiness - Jul 30, 2008
Participants should go to the Web site at least 5 minutes prior to the scheduled start time of the event to register. A slideshow will accompany the webcast ...EEFT
Geron Corporation Reports 2008 Second Quarter Financial Results ...
MarketWatch - Jul 30, 2008
For the second quarter of 2008, the company reported a net loss of $13.6 million, or $(0.17) per share, compared to $14.0 million, or $(0.19) per share, ...GERN
Source: Google News

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
... 0.17 ... Legal central bank in- depen- dence" (index) of 0.69 0.64 0.61 0.50 0.48 0.45
0.44 0.42 0.36 0.34 0.33 0.29 0.28 0.27 0.25 0.24 0.24 0.23 0.18 0.17 0.17 ...

[PDF] Phylogenetic constraints and adaptation explain food-web structure -
MF Cattin, LF Bersier, C Banasek-Richter, R … - Nature, 2004 - unifr.ch
... by one order of magnitude?in the prediction of these standard food-web descriptors. ...
0] 0.10 0.14 [0.28] 0.15 0.08 [0.38] 0.07 0.06 [0] 0.08 0.09 [0.17] 0.08 ...
-

Co-adapted foraging traits in a guild of orb-weaving spiders
CW Olive - Oecologia, 1981 - Springer
... Leg length - 0.18 - 0.52 0.25 Paturon length 0.70 0.18 0.09 Fang length 0.99 -0.05
-0.17 Web height 0.52 - 0.26 0.22 Mesh width -0.17 0.72 0.17 ...

The calculation of web impact factors -
P Ingwersen - Journal of Documentation, 1998 - ingentaconnect.com
... A typical top-down web impact factor calculation gives 1.020 as, what we call ... former
differ- ences are ?2.44% and ?2.61% whilst the latter is -0.17% for the ...

Contact Sex Signals on Web and Cuticle of Tegenaria atrica (Araneae, Agelenidae) -
O Prouvost, M Trabalon, M Papke, S Schulz - Archives of Insect Biochemistry and Physiology, 1999 - doi.wiley.com
... Receptive females Unreceptive females Determination Web Cuticle Web Cuticle Acids
Tridecanoic 0.17 (0.04) 0.06 (0.03) Tetradecanoic 1.85 (1.11) 0.15 (0.06) ...

Spiral geometry in the garden spider's orb web -
F Vollrath, W Mohren - Naturwissenschaften, 1985 - Springer
... 2s = 2.54 + sd 1.09 (2r = 0.643 + 0.118) for all joints and 2=0.93+sd 0.17 07r=0.814 ...
This is due tO the fact that the web of A. diadematus is not a perfectly ...

Cost estimation for web applications -
M Ruhe, R Jeffery, I Wieczorek - Software Engineering, 2003. Proceedings. 25th International …, 2003 - ieeexplore.ieee.org
... With the growing importance of web applications in general business matters, many
practitioners see the measurement of web applications as a particularly ...

Web-based telerobotics -
K Taylor, B Dalton, J Trevelyan - Robotica, 1999 - Cambridge Univ Press
... Hip locations of the legs in {B} Hip locations Hip 1 (0.287, 0.17, 0) Hip 2 (0.287,
0.17, 0) Hip 3 ( 0.287, 0.17, 0) Hip 4 ( 0.287, 0.17, 0) Gait stability 61 ...

Looking for linking: associative links on the Web -
T Miles-Board, L Carr, W Hall - Proceedings of the thirteenth ACM conference on Hypertext …, 2002 - portal.acm.org
... Links Density Mean 27 0.17 Median 14 0.12 Standard Deviation 60.66 0.17 ... The Internet
Archive 2 provides a digital library of crawled Web sites, consisting of ...

Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. -
J Casals-Stenzel, G Muacevic, KH Weber - J Pharmacol Exp Ther, 1987 - ncbi.nlm.nih.gov
... human platelet and neutrophil aggregation in vitro (IC50 = 0.17 and 0.36 ... In comparison
with kadsurenone, ketotifen or thiazinamium chloride, WEB 2086 was 26 to ...

Source: Google Scholar
 
 

Testosterone Replacement Therapy Appears Safe For Prostate

Article Date: 18 Nov 2006 - 14:00pm (PST)
Preliminary research suggests that testosterone replacement therapy for men with low testosterone levels appears to have little effect on the prostate gland, contrary to some reports that this therapy may be harmful, according to a study in the November 15 issue of JAMA, a theme issue on men's health.

Leonard S. Marks, M.D., of the Urological Sciences Research Foundation and University of California, Los Angeles, presented the findings of the study today at a JAMA media briefing on men's health in New York.

Testosterone replacement therapy (TRT) in aging men is a widespread, growing practice. According to pharmaceutical industry estimates, more than 1.8 million prescriptions for testosterone products were written in the United States in 2002, a 30 percent increase over the previous year and a 170 percent increase over the previous 5 years. In 2005, a total of 2.3 million prescriptions were written for these products. Serum levels of testosterone decline with age, and many aging men with low levels of the hormone may experience depression, sexual dysfunction, diminished lean body mass, muscle volume and strength, and reduced bone mineral density, according to background information in the article. Such changes, in association with low testosterone levels, have been called "male menopause."

Article continues below and (thank you)

 
Aspects of the syndrome may be improved with TRT, and most testosterone prescriptions are currently written for men older than 45 years, a demographic in which prostate disease is most common. Between 2 and 4 million men, nearly all in this "prostatic age group," may be candidates for treatment, the authors write. In men with advanced prostate cancer, testosterone administration often worsens the disease. Thus, when aging men receive supplemental testosterone, a primary concern is prostate safety. Even in men with no sign of prostate cancer, the possibility of stimulating growth in subclinical disease exists. Instances of prostate cancer in men receiving testosterone supplementation have been reported. When TRT is prescribed, careful monitoring for prostate disease is considered mandatory. But there is little information regarding the effects of TRT on prostate tissue in men.

Dr. Marks and colleagues conducted a randomized controlled trial to assess the effects of TRT on prostate tissue of 44 men, age 44 to 78 years, with low serum testosterone levels. The study was conducted between February 2003 and November 2004. Participants were randomly assigned to receive by injection 150 mg of replacement testosterone or matching placebo every 2 weeks for 6 months. Of the 44 men randomized, 40 had prostate biopsies performed both at baseline and at the end of the study and were included in the final analysis (TRT, n = 21; placebo, n = 19).
 
Testosterone replacement therapy increased serum testosterone levels to the mid-normal range with no significant change in serum testosterone levels in matched, placebo-treated men. In prostate tissue, TRT increased median (midpoint) androgen (male sex hormone) concentrations only slightly compared with baseline levels or between the 2 groups. No treatment-related change was observed in prostate histology, tissue biomarkers, gene expression, or cancer incidence or severity. Treatment-related changes in prostate volume, serum prostate-specific antigen, voiding symptoms, and urinary flow were slight.

"- under the conditions herein, including the biopsy to detect cancer performed pretreatment, a degree of prostate safety is defined for men undergoing TRT," the authors write. "The prostate risks to men undergoing TRT may not be as great as once believed, especially if the results of the pretreatment biopsy are negative. However, establishment of prostate safety for large populations of older men undergoing longer duration of TRT requires further study," the researchers conclude.

###

(JAMA. 2006;296:2351-2361.)

This study was supported by unrestricted educational grants from Watson Laboratories (Salt Lake City) and Solvay Pharmaceuticals (Marietta, Ga.); a National Institutes of Health/National Cancer Institute Spore grant (Drs. Epstein, Veltri, Makarov, and Partin); a National Institutes of Health grant (Dr. Hess); the Prostate Cancer Foundation (Dr. Nelson); a National Institutes of Health/National Cancer Institute Spore grant; and a National Institutes of Health grant (Drs. Mostaghel and Nelson). Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Contact: Rachel Champeau
JAMA and Archives Journals
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 

 © 2002-2006

Keywords::

Contact Iconocast

Home Page